BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Lupin appoints Claus Jepsen as President, Global Specialty

22 October 2024 | News

Claus joins Lupin from Takeda Pharmaceuticals, where he led the Global Strategy for Rare Diseases.



Global pharma major Lupin Limited (Lupin) announced the appointment of Claus Jepsen as President, Global Specialty. He brings over three decades of experience in commercial strategy, portfolio management, and launch planning across Europe, Asia, and the United States. Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 22,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Claus joins Lupin from Takeda Pharmaceuticals, where he led the Global Strategy for Rare Diseases. Prior to that Claus was at GlaxoSmithKline, where he served in many roles including country head in Asia, and Global franchise management in Immunology, Respiratory and Neurology therapeutic areas. Claus has launched major brands like Ellipta in the U.S. and led Advair and Seretide success in Europe and U.S.

Commenting on the appointment, Lupin’s CEO, Vinita Gupta said, “We are delighted to welcome Claus to our executive leadership team. His experience in leading specialty strategy, commercial planning and portfolio choices across key markets will enable us to build our Specialty brand business.”